Invivyd, Inc.

Invivyd reported that PEMGARDA revenue increased 22% year over year in Q1 2026. The company said the first quarter included meaningful clinical spend for the DECLARATION trial, which it described as a substantial investment relative to ordinary clinical and SG&A spending. Management did not give quarterly revenue, EPS, gross margin, or cash-balance figures in the prepared remarks. Forward-looking commentary centered on continued PEMGARDA growth, completion of DECLARATION imminently, a return to more normalized R&D spending as VYD2311 winds up over the coming quarters, and preparation for VYD2311 commercialization if approved.

Marc Elia framed the quarter as part of a broader strategic buildout around infectious disease monoclonal antibodies, emphasizing VYD2311, government affairs, and a broader early discovery pipeline beyond COVID. He repeatedly stressed that demand and recruitment have been strong, that the company views the platform as potentially broader than one product, and that the business is educating policymakers and the public on antibody science. His tone was highly confident and promotional, with frequent emphasis on opportunity, public health relevance, and long-term shareholder value.

Bill Duke said Q1 2026 included meaningful clinical spend tied to DECLARATION, calling it a very substantial investment but one with extraordinary commercial potential. He said the cash position remains very strong, helped by additional cash raised in April from long-term investors through the ATM facility. He also said that as the pivotal trial for VYD2311 winds up over the coming quarters, R&D spending should become more normalized, and noted targeted investments in commercialization infrastructure that could also support PEMGARDA.

Analysts focused on whether the 30-minute post-administration monitoring time could end up in the label and whether it would affect adoption; management said it was too early to know, but they do not view it as a meaningful adoption risk and expect future practice to look more like vaccine monitoring. Questions also probed the clinical and commercial bar for VYD2311 efficacy, single-dose versus monthly dosing, and what the surveillance environment looks like for COVID waves. Management answered that they expect a favorable risk-benefit profile even at low efficacy, but said the dose and study design were intended to support much stronger protection; they also said surveillance remains sufficient to time prophylaxis around waves and that the monitoring window for vaccines is no longer specified on labels, which they expect will be similar for VYD2311.